Low dose inhaled nitric oxide in patients with acute lung injury

Submission date 18/11/2011	Recruitment status No longer recruiting	Prospectively registered	
		[] Protocol	
Registration date 31/01/2012	Overall study status Completed	Statistical analysis plan	
		[X] Results	
Last Edited 31/01/2012	Condition category Injury, Occupational Diseases, Poisoning	Individual participant data	

Plain English summary of protocol

Background and study aims

Acute respiratory distress syndrome (ARDS) is a disease in which the lungs are inflamed, wet and there is difficulty transmitting oxygen from the air that enters the lung as part of the breathing process into the blood. It has many causes including infectious and non-infectious. The objectives of this study were to add a gas called nitric oxide(NO) to the air that participants were breathing in order to raise the oxygen level in the blood in hopes of improving outcome in participants with ARDS.

Who can participate?

Patients aged 18 and over, regardless of sex, who have ARDS and are on a breathing machine (called a ventilator) in order to enable oxygen transfer into the blood.

What does the study involve?

The study compared inhaled nitric oxide (INO) added to the air the patient was breathing though the machine with a placebo nitrogen, a safe gas that makes up most of the air that we breathe and would have no effect on ARDS. All participants will receive the same treatment that they would have received for ARDS, even if they had not participated in the study. If patients were randomly allocated to the group receiving inhaled nitric oxide, this would have been the additional therapy.

What are the possible benefits and risks of participating? By participating it is possible that the subject will have improved oxygenation and that this may lead to improved outcome. There are no anticipated potential side effects of the treatment when delivered at the doses that will be used in this study.

Where is the study run from?

There were 35 centers taking part in this trial and the lead center is St. Johns Mercy Hospital St. Louis, Missouri.

When is study starting and how long is it expected to run for? The start date of the study was 1996 and the duration of the study was approximately 3 years. Recruitment of participants was until late summer/fall 1999. Who is funding the study? The study was funded by INO Therapeutics (Now called IKARIA). They paid the costs associated with the trial.

Who is the main contact? Phil Dellinger dellinger-phil@cooperhealth.edu

Contact information

Type(s) Scientific

Contact name Dr Richard Dellinger

Contact details Cooper University Hospital One Cooper Plaza Camden, New Jersey United States of America 19102 +1 856 342 2632 dellinger-phil@cooperhealth.edu

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers INOT06

Study information

Scientific Title Low dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial

Study objectives To evaluate the clinical efficacy of low-dose (5-ppm) inhaled nitric oxide in patients with acute lung injury.

Ethics approval required Old ethics approval format

Ethics approval(s)

Human Subjects Committee (USA), 15 February 1996

Study design Multicenter randomized blinded placebo-controlled

Primary study design Interventional

Secondary study design Randomised controlled trial

Study setting(s) Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Acute lung injury

Interventions

Inhaled nitric oxide (5ppm) or placebo (nitrogen gas) is delivered with mechanical ventilator breaths until the patient is extubated or for a total of 28 days.

Intervention Type

Drug

Phase Not Applicable

Drug/device/biological/vaccine name(s) Nitric oxide

Primary outcome measure Days alive and off mechanical ventilation

Secondary outcome measures

Pulmonary function including spirometry, lung volumes and diffusion of carbon monoxide evaluated at 6 months

Overall study start date

27/03/1996

Completion date 08/09/1999

Eligibility

Key inclusion criteria

1. Mechanically ventilated patients with acute lung injury

2. Ratio of partial pressure of arterial oxygen (O2) to the fraction of inspired partial pressure of oxygen in arterial blood/fraction of inspired oxygen (Pa02/FiO2) ratio of 250 or less

Participant type(s)

Patient

Age group

Adult

Sex Both

Target number of participants 385

Key exclusion criteria Sepsis as the cause of the acute lung injury

Date of first enrolment 27/03/1996

Date of final enrolment 08/09/1999

Locations

Countries of recruitment United States of America

Study participating centre Cooper University Hospital Camden, New Jersey United States of America 19102

Sponsor information

Organisation Ohmeda/INO Therapeutics Inc (USA)

Sponsor details

c/o Ikaria Inc Perryville III Corporate Park 53 Frontage Road Hampton, New Jersey United States of America 08827

Sponsor type Industry

Website http://www.ikaria.com

Funder(s)

Funder type Industry

Funder Name Ohmeda PPD/INO Therapeutics Inc. (USA)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	07/04/2004		Yes	No